Travere Therapeutics (TVTX) Stock Forecast & Price Target

Compare

532 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TVTX Analyst Ratings

Strong Buy

12 Buy

2 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Travere

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TVTX Stock 12 Month Forecast

Average Price Target

$39.91

▲(23.41% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $39.91 with a high forecast of $48.00 and a low forecast of $31.00. The average price target represents a 23.41% change from the last price of $32.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","22":"$22","31":"$31","40":"$40","49":"$49"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,22,31,40,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.16,36.1476923076923,37.13538461538461,38.12307692307692,39.11076923076923,40.098461538461535,41.08615384615384,42.073846153846155,43.06153846153846,44.04923076923077,45.036923076923074,46.02461538461539,47.012307692307694,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.16,35.52538461538461,35.89076923076923,36.25615384615384,36.62153846153846,36.98692307692308,37.35230769230769,37.7176923076923,38.083076923076916,38.44846153846154,38.81384615384615,39.17923076923076,39.54461538461538,{"y":39.91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.16,34.839999999999996,34.519999999999996,34.199999999999996,33.879999999999995,33.559999999999995,33.239999999999995,32.92,32.6,32.28,31.96,31.64,31.32,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.57,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.4,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.44,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.76,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.79,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$48.00

Average Price Target$39.91

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Pantginis

H.C. Wainwright

$30→$47

Buy

45.33%

Upside

Reiterated

11/10/25

Positive Outlook for Travere Therapeutics: FILSPARI's Advancements in Reducing Proteinuria and Long-term Kidney Failure Risk

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

11/07/25

Optimistic Buy Rating for Travere Therapeutics Driven by Filspari's Market Potential and Strategic Positioning

Allison Bratzel

Piper Sandler

$26→$35

Hold

8.23%

Upside

Reiterated

11/04/25

Travere Therapeutics price target raised to $35 from $26 at Piper SandlerTravere Therapeutics price target raised to $35 from $26 at Piper Sandler

Jason Zemansky

Bank of America Securities

$39

Buy

20.59%

Upside

Reiterated

11/04/25

Bank of America Securities Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Edward Nash

Canaccord Genuity

$47

Buy

45.33%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Vanda (NASDAQ: VNDA) and Travere Therapeutics (NASDAQ: TVTX)

Alex Thompson CFA

Stifel Nicolaus

$25→$31

Hold

-4.14%

Downside

Reiterated

11/03/25

Travere Therapeutics (TVTX) Receives a Hold from Stifel Nicolaus

Yigal Nochomovitz

Citi

$48

Buy

48.42%

Upside

Assigned

10/31/25

Citi ups Travere target, opens 'upside 90-day catalyst watch'Citi ups Travere target, opens 'upside 90-day catalyst watch'

Tyler Van Buren

TD Cowen

$30→$40

Buy

23.69%

Upside

Reiterated

10/30/25

Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential

Vamil Divan

Guggenheim

$47

Buy

45.33%

Upside

Reiterated

10/05/25

Travere Therapeutics (TVTX) Receives a Buy from Guggenheim

Gavin Clark-Gartner

Evercore ISI

$45→$35

Buy

8.23%

Upside

Reiterated

10/01/25

Evercore ISI Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

09/11/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Travere Therapeutics (TVTX)

Mohit Bansal

Wells Fargo

$27→$35

Buy

8.23%

Upside

Reiterated

09/11/25

Travere Therapeutics price target raised to $35 from $27 at Wells FargoTravere Therapeutics price target raised to $35 from $27 at Wells Fargo

Maury Raycroft

Jefferies

$35

Buy

8.23%

Upside

Reiterated

09/10/25

AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

09/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

Laura Chico

Wedbush

$30→$32

Buy

-1.05%

Downside

Reiterated

08/07/25

Travere Therapeutics price target raised to $32 from $30 at WedbushTravere Therapeutics price target raised to $32 from $30 at Wedbush

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Pantginis

H.C. Wainwright

$30→$47

Buy

45.33%

Upside

Reiterated

11/10/25

Positive Outlook for Travere Therapeutics: FILSPARI's Advancements in Reducing Proteinuria and Long-term Kidney Failure Risk

Anupam Rama

J.P. Morgan

―

Buy

―

Reiterated

11/07/25

Optimistic Buy Rating for Travere Therapeutics Driven by Filspari's Market Potential and Strategic Positioning

Allison Bratzel

Piper Sandler

$26→$35

Hold

8.23%

Upside

Reiterated

11/04/25

Travere Therapeutics price target raised to $35 from $26 at Piper SandlerTravere Therapeutics price target raised to $35 from $26 at Piper Sandler

Jason Zemansky

Bank of America Securities

$39

Buy

20.59%

Upside

Reiterated

11/04/25

Bank of America Securities Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

Edward Nash

Canaccord Genuity

$47

Buy

45.33%

Upside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Vanda (NASDAQ: VNDA) and Travere Therapeutics (NASDAQ: TVTX)

Alex Thompson CFA

Stifel Nicolaus

$25→$31

Hold

-4.14%

Downside

Reiterated

11/03/25

Travere Therapeutics (TVTX) Receives a Hold from Stifel Nicolaus

Yigal Nochomovitz

Citi

$48

Buy

48.42%

Upside

Assigned

10/31/25

Citi ups Travere target, opens 'upside 90-day catalyst watch'Citi ups Travere target, opens 'upside 90-day catalyst watch'

Tyler Van Buren

TD Cowen

$30→$40

Buy

23.69%

Upside

Reiterated

10/30/25

Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential

Vamil Divan

Guggenheim

$47

Buy

45.33%

Upside

Reiterated

10/05/25

Travere Therapeutics (TVTX) Receives a Buy from Guggenheim

Gavin Clark-Gartner

Evercore ISI

$45→$35

Buy

8.23%

Upside

Reiterated

10/01/25

Evercore ISI Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

Joseph Schwartz

Leerink Partners

―

Buy

―

Reiterated

09/11/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Travere Therapeutics (TVTX)

Mohit Bansal

Wells Fargo

$27→$35

Buy

8.23%

Upside

Reiterated

09/11/25

Travere Therapeutics price target raised to $35 from $27 at Wells FargoTravere Therapeutics price target raised to $35 from $27 at Wells Fargo

Maury Raycroft

Jefferies

$35

Buy

8.23%

Upside

Reiterated

09/10/25

AdCom cancellation 'clear positive' for Travere Therapeutics, says JefferiesAdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

09/10/25

Cantor Fitzgerald Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

Laura Chico

Wedbush

$30→$32

Buy

-1.05%

Downside

Reiterated

08/07/25

Travere Therapeutics price target raised to $32 from $30 at WedbushTravere Therapeutics price target raised to $32 from $30 at Wedbush

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Travere Therapeutics

1 Month

xxx

Success Rate

14/20 ratings generated profit

Average Return

+8.96%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +8.96% per trade.

3 Months

xxx

Success Rate

13/20 ratings generated profit

Average Return

+15.10%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +15.10% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

11/14 ratings generated profit

Average Return

+57.32%

reiterated a buy rating 12 days ago

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +57.32% per trade.

2 Years

xxx

Success Rate

12/14 ratings generated profit

Average Return

+102.45%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +102.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TVTX Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TVTX has received 19 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. TVTX average Analyst price target in the past 3 months is 39.91.

Each month's total comprises the sum of three months' worth of ratings.

TVTX Financial Forecast

TVTX Earnings Forecast

Next quarter’s earnings estimate for TVTX is -$0.07 with a range of -$0.31 to $0.28. The previous quarter’s EPS was $0.28. TVTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TVTX has Performed in-line its overall industry.

TVTX Sales Forecast

Next quarter’s sales forecast for TVTX is $141.18M with a range of $115.18M to $183.96M. The previous quarter’s sales results were $164.86M. TVTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TVTX has Performed in-line its overall industry.

TVTX Stock Forecast FAQ

What is TVTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Travere Therapeutics’s 12-month average price target is 39.91.

What is TVTX’s upside potential, based on the analysts’ average price target?

Travere Therapeutics has 23.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TVTX a Buy, Sell or Hold?

Travere Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 2 hold ratings and 0 sell ratings.

What is Travere Therapeutics’s price target?

The average price target for Travere Therapeutics is 39.91. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $48.00 ,the lowest forecast is $31.00. The average price target represents 23.41% Increase from the current price of $32.34.

What do analysts say about Travere Therapeutics?

Travere Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of TVTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Travere Therapeutics (TVTX) Stock Forecast & Price Target

TVTX Analyst Ratings

TVTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Travere Therapeutics

TVTX Analyst Recommendation Trends

TVTX Financial Forecast

TVTX Earnings Forecast

TVTX Sales Forecast

TVTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts